| 10.34 0.88 (9.3%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.88 |
1-year : | 14.59 |
| Resists | First : | 11.03 |
Second : | 12.5 |
| Pivot price | 10.63  |
|||
| Supports | First : | 8.65 |
Second : | 7.2 |
| MAs | MA(5) : | 9.63 |
MA(20) : | 10.79 |
| MA(100) : | 9.7 |
MA(250) : | 9.05 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 24.7 |
D(3) : | 17.3 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 18.32 | Low : | 3.21 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IOVA ] has closed above bottom band by 41.8%. Bollinger Bands are 17.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.56 - 10.6 | 10.6 - 10.64 |
| Low: | 9.36 - 9.4 | 9.4 - 9.45 |
| Close: | 10.27 - 10.34 | 10.34 - 10.42 |
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Sat, 14 Sep 2024
Iovance Biotherapeutics, Inc. (IOVA): Short Seller Sentiment is Bearish on This Cancer Stock - Yahoo Finance
Wed, 11 Sep 2024
10 Worst Cancer Stocks To Buy Now According to Short Sellers - Insider Monkey
Tue, 03 Sep 2024
Iovance Biotherapeutics to Present at Upcoming Conferences - StockTitan
Tue, 13 Aug 2024
Industry Analysts Just Made A Sizeable Upgrade To Their Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Revenue Forecasts - Yahoo Finance
Mon, 29 Jul 2024
Here’s Why Iovance Biotherapeutics (IOVA) Declined in Q2 - Yahoo Finance
Mon, 08 Jul 2024
Is Iovance Biotherapeutics, Inc. (IOVA) One of the Most Shorted Stocks Loved by Analysts? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 304 (M) |
| Held by Insiders | 2.2432e+008 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 61,320 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.3925e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -327.7 % |
| Return on Assets (ttm) | -33.4 % |
| Return on Equity (ttm) | -65.4 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 1539.2 |
| Sales Per Share | 5.20159e+007 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -389 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0.3 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.51 |
| Dividend | 0 |
| Forward Dividend | 5.769e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|